search
Back to results

A Study of Below The Knee Arteries' Stenosis or Occlusion Treated With LEGFLOW OTW

Primary Purpose

Peripheral Artery Disease

Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Paclitaxel Releasing Peripheral Balloon Dilatation Catheter
PTA catheter
Sponsored by
ZhuHai Cardionovum Medical Device Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Peripheral Artery Disease focused on measuring drug eluting balloon, arterial vasculature below the knee

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • age from 18 to 85 years (include 18 and 85 year);
  • critical limb ischemia subjects (Rutherford classification from 3 to 6)
  • expective survival more than 1 year;
  • can understand the study objective, self willing enrolls and sign the informed consent, and accept scheduled followed up at the specific time.

Angiographic inclusive criteria:

  • reference vessel diameter 2.0-3.5mm;
  • stenosis or occlusion in arterial vasculature below the knee shall have distal outflow;
  • target lesion stenosis ≥70% or occlusion, length ≤270mm;
  • if subject has ipsilateral / contralateral iliac lesions, the iliac lesion shall meet all the following criteria:

    • iliac lesion or occlusion length ≤100mm and
    • shall be treated earlier than the target lesion and
    • shall be treated successfully. the successful treatment standard: 1) residual stenosis <30%; 2) without flow limiting dissection 3) without thrombosis, embolism or any other serious adverse events

Exclusion Criteria:

  • subjects currently participate in other drugs or medical devices clinical study and have not reach the primary endpoint;
  • childbearing aged women whose pregnancy test before intervention operation is not negative, and lactating mothers;
  • subjects with renal function insufficiency (serum creatinine> 2.5mg / dL or in renal dialysis);
  • subjects have known be allergy or contraindication to the contrast agent, paclitaxel, heparin, antiplatelet, anticoagulant or thrombolytic agents;
  • subjects plan to a major amputation (over metatarsal level);
  • stroke subjects within 3 months or stroke subjects with severe hemiplegia and aphasia associated sequelaes over 3 months before the intervention operation;
  • subjects with acute myocardial infarction, thrombolytic therapy or angina within 30 days before the intervention operation;
  • subjects whose target lesion limb have gangrene (the gangrene range over the metatarsophalangeal joint);
  • target lesion is a stenosis or occlusion that have prior been treated by scaffold implantation, DEB, ordinary balloon catheter or bypass graft;
  • lesions and /or occlusion locate or extend to popliteal artery or below ankle joint;
  • subjects requiring be intervention in bilateral lower limb;
  • the stenosis lesion of ipsilateral femoral artery or ipsilateral popliteal artery have a diameter stenosis ≥50% untreated before the intervention operation;
  • ipsilateral femoral artery or ipsilateral popliteal artery has single or adjacent lesion length ≥15cm, or ipsilateral femoral artery or ipsilateral popliteal artery has multiple lesion and one of these multiple lesion length ≥10cm or occlusion;
  • - adjacent lesion: 1) interval no more than 30 mm, 2) can be treated as a single lesion;
  • - multiple lesion: 1) interval no more than 30 mm, 2) need to be treated as multiple lesion;
  • the residual stenosis still ≥30%, even when the length <15cm and stenosis ≥50% single or adjacent lesion in ipsilateral femoral artery or ipsilateral popliteal artery has been treated, or when each lesion length <10cm and stenosis ≥50% multiple lesion in ipsilateral femoral artery or ipsilateral popliteal artery has been treated;
  • DES and /or DEB has been used in the inflow vessel of lesions treatment;
  • subject has no patency vessel below the ankle artery before the intervention operation;
  • target vessel aneurysm;
  • acute or subacute thrombosis in target vessel;
  • angiography shows severe calcification in the target lesion (before contrast injection or digital subtraction angiography, intensive annular calcifications that make target lesion not expansion and / or a calcification within the target lesion and locate on either sides of the vessel wall whose continuous length over than 5cm);
  • lesions that the guild wire cannot pass through;
  • subjects need be treated by thrombus endarterectomy, percutaneous transluminal plaque circumcision or laser treatment device indicate by intraoperative angiography;

Sites / Locations

  • The First Affiliated Hospital of Fujian Medical UniversityRecruiting
  • Hainan General HospitalRecruiting
  • Hebei General HospitalRecruiting
  • The First Hospital of Hebei Medical UniversityRecruiting
  • Xiangya Hospital Central South University
  • Jiangsu Province HospitalRecruiting
  • The Second Affiliated Hospital of Nanchang University
  • The First Affiliated Hospital of Xi'an Jiaotong UniversityRecruiting
  • West China Hospital, Sichuan UniversityRecruiting
  • Beijing Anzhen Hospital Capital Medical UniversityRecruiting
  • Beijing Chao-Yang HospitalRecruiting
  • Beijing Frendship Hospital, Capital Medical UniversityRecruiting
  • Beijing HospitalRecruiting
  • Beijing Shijitan Hospital, Capital Medical UniversityRecruiting
  • Chinese PLA General HospitalRecruiting
  • Fuwai Hospital, Chinese Accadamy of Medical SciencesRecruiting
  • Renji Hospital Shanghai Jiaotong University School of Medicine
  • Shanghai Ninth people's Hospital, Shanghai Jiaotong University School of MedicineRecruiting
  • Tianjing Medical University General HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

LEGFLOW OTW group

AMPHIRION DEEP group

Arm Description

in the LEGFLOW OTW group the subject will be treated by the Paclitaxel Releasing Peripheral Balloon Dilatation Catheter (LEGFLOW)

in the AMPHIRION DEEP group the subject will be treated by PTA catheter (AMPHIRION DEEP)

Outcomes

Primary Outcome Measures

Target lesion restenosis determined by CTA
Restenosis defined as within the ± 5mm range beyond proximal and / or distal of target lesion, the lumen loss is greater than 50% of the reference vessel lumen diameter (RVD) follow-up by CTA. Target lesion revascularization (TLR): clinical symptoms of peripheral arterial disease recurrence or worsening, and any target lesion re-intervention caused by diameter stenosis ≥50% (confirmed by Doppler ultrasound, DSA or CT angiography).

Secondary Outcome Measures

device success rate
device success defines as: the device successfully delivered to the target location, inflated, deflated and withdrawn from the treated balloon inflation tube.
operation success rate
operation success defines as: the blood supply of the target lesion regained after treatment, residual stenosis less than 50% and without flow-limiting dissection (≥type D) occurred.
clinical success rate
clinical success defines as: operation success, and without any postoperative complication before discharge (death, lesions limb amputation, target lesion thrombosis or TVR)
change of the Rutherford score
change of the life equality by EQ5D
target limb ulcer healing rate
healing or not, if not: improve, no change, or progression;
target lesion revascularization rate
target limb upper amputation and lower amputation rate
major adverse event rate including all cause death, target limb upper amputation and target lesion revascularization

Full Information

First Posted
November 7, 2016
Last Updated
November 27, 2018
Sponsor
ZhuHai Cardionovum Medical Device Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT02962232
Brief Title
A Study of Below The Knee Arteries' Stenosis or Occlusion Treated With LEGFLOW OTW
Official Title
Evaluation the Safety and Efficacy of the Paclitaxel Releasing Peripheral Balloon Dilatation Catheter (LEGFLOW)in Treatment of Stenosis or Occlusion in Below The Knee Arteries: A Prospective, Multicenter, Randomized, Controlled Clinical Study
Study Type
Interventional

2. Study Status

Record Verification Date
November 2018
Overall Recruitment Status
Unknown status
Study Start Date
November 2016 (undefined)
Primary Completion Date
June 2020 (Anticipated)
Study Completion Date
December 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
ZhuHai Cardionovum Medical Device Co., Ltd.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
To evaluate the safety and efficacy of the Paclitaxel Releasing Peripheral Balloon Dilatation Catheter (LEGFLOW) compared to the PTA catheter (AMPHIRION DEEP) in treatment of stenosis or occlusion in below the knee artery.
Detailed Description
To evaluate the safety and efficacy of the Paclitaxel Releasing Peripheral Balloon Dilatation Catheter (LEGFLOW) compared to the PTA catheter (AMPHIRION DEEP) in treatment of stenosis or occlusion inbelow the knee artery. This is a prospective, multi-center, randomized, control, opening, superiority designed clinical study. Plan to enroll 172 eligible subjects in 15 centers in China, all these subjects will be randomized 1:1 to the study group (LEGFLOW OTW group, n=86) and control group (AMPHIRION DEEP group, n=86), and accept the treatment of LEGFLOW OTW and AMPHIRION DEEP respectively.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Artery Disease
Keywords
drug eluting balloon, arterial vasculature below the knee

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
172 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
LEGFLOW OTW group
Arm Type
Experimental
Arm Description
in the LEGFLOW OTW group the subject will be treated by the Paclitaxel Releasing Peripheral Balloon Dilatation Catheter (LEGFLOW)
Arm Title
AMPHIRION DEEP group
Arm Type
Active Comparator
Arm Description
in the AMPHIRION DEEP group the subject will be treated by PTA catheter (AMPHIRION DEEP)
Intervention Type
Device
Intervention Name(s)
Paclitaxel Releasing Peripheral Balloon Dilatation Catheter
Other Intervention Name(s)
LEGFLOW OTW
Intervention Description
treatment group
Intervention Type
Device
Intervention Name(s)
PTA catheter
Other Intervention Name(s)
AMPHIRION DEEP
Intervention Description
control group
Primary Outcome Measure Information:
Title
Target lesion restenosis determined by CTA
Description
Restenosis defined as within the ± 5mm range beyond proximal and / or distal of target lesion, the lumen loss is greater than 50% of the reference vessel lumen diameter (RVD) follow-up by CTA. Target lesion revascularization (TLR): clinical symptoms of peripheral arterial disease recurrence or worsening, and any target lesion re-intervention caused by diameter stenosis ≥50% (confirmed by Doppler ultrasound, DSA or CT angiography).
Time Frame
6 month post procedure
Secondary Outcome Measure Information:
Title
device success rate
Description
device success defines as: the device successfully delivered to the target location, inflated, deflated and withdrawn from the treated balloon inflation tube.
Time Frame
at 0-30 days
Title
operation success rate
Description
operation success defines as: the blood supply of the target lesion regained after treatment, residual stenosis less than 50% and without flow-limiting dissection (≥type D) occurred.
Time Frame
at 0-30 days
Title
clinical success rate
Description
clinical success defines as: operation success, and without any postoperative complication before discharge (death, lesions limb amputation, target lesion thrombosis or TVR)
Time Frame
at 0-30 days
Title
change of the Rutherford score
Time Frame
in day 0-30, 6th month, 12th month post operation
Title
change of the life equality by EQ5D
Time Frame
in day 0-30, 6th month, 12th month post operation compares to baseline
Title
target limb ulcer healing rate
Description
healing or not, if not: improve, no change, or progression;
Time Frame
in day 0-30, 6th month, 12th month post operation
Title
target lesion revascularization rate
Time Frame
in day 0-30, 6th month, 12th month post operation
Title
target limb upper amputation and lower amputation rate
Time Frame
in day 0-30, 6th month, 12th month post operation
Title
major adverse event rate including all cause death, target limb upper amputation and target lesion revascularization
Time Frame
in day 0-30, 6th month, 12th month post operation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: age from 18 to 85 years (include 18 and 85 year); critical limb ischemia subjects (Rutherford classification from 3 to 6) expective survival more than 1 year; can understand the study objective, self willing enrolls and sign the informed consent, and accept scheduled followed up at the specific time. Angiographic inclusive criteria: reference vessel diameter 2.0-3.5mm; stenosis or occlusion in arterial vasculature below the knee shall have distal outflow; target lesion stenosis ≥70% or occlusion, length ≤270mm; if subject has ipsilateral / contralateral iliac lesions, the iliac lesion shall meet all the following criteria: iliac lesion or occlusion length ≤100mm and shall be treated earlier than the target lesion and shall be treated successfully. the successful treatment standard: 1) residual stenosis <30%; 2) without flow limiting dissection 3) without thrombosis, embolism or any other serious adverse events Exclusion Criteria: subjects currently participate in other drugs or medical devices clinical study and have not reach the primary endpoint; childbearing aged women whose pregnancy test before intervention operation is not negative, and lactating mothers; subjects with renal function insufficiency (serum creatinine> 2.5mg / dL or in renal dialysis); subjects have known be allergy or contraindication to the contrast agent, paclitaxel, heparin, antiplatelet, anticoagulant or thrombolytic agents; subjects plan to a major amputation (over metatarsal level); stroke subjects within 3 months or stroke subjects with severe hemiplegia and aphasia associated sequelaes over 3 months before the intervention operation; subjects with acute myocardial infarction, thrombolytic therapy or angina within 30 days before the intervention operation; subjects whose target lesion limb have gangrene (the gangrene range over the metatarsophalangeal joint); target lesion is a stenosis or occlusion that have prior been treated by scaffold implantation, DEB, ordinary balloon catheter or bypass graft; lesions and /or occlusion locate or extend to popliteal artery or below ankle joint; subjects requiring be intervention in bilateral lower limb; the stenosis lesion of ipsilateral femoral artery or ipsilateral popliteal artery have a diameter stenosis ≥50% untreated before the intervention operation; ipsilateral femoral artery or ipsilateral popliteal artery has single or adjacent lesion length ≥15cm, or ipsilateral femoral artery or ipsilateral popliteal artery has multiple lesion and one of these multiple lesion length ≥10cm or occlusion; - adjacent lesion: 1) interval no more than 30 mm, 2) can be treated as a single lesion; - multiple lesion: 1) interval no more than 30 mm, 2) need to be treated as multiple lesion; the residual stenosis still ≥30%, even when the length <15cm and stenosis ≥50% single or adjacent lesion in ipsilateral femoral artery or ipsilateral popliteal artery has been treated, or when each lesion length <10cm and stenosis ≥50% multiple lesion in ipsilateral femoral artery or ipsilateral popliteal artery has been treated; DES and /or DEB has been used in the inflow vessel of lesions treatment; subject has no patency vessel below the ankle artery before the intervention operation; target vessel aneurysm; acute or subacute thrombosis in target vessel; angiography shows severe calcification in the target lesion (before contrast injection or digital subtraction angiography, intensive annular calcifications that make target lesion not expansion and / or a calcification within the target lesion and locate on either sides of the vessel wall whose continuous length over than 5cm); lesions that the guild wire cannot pass through; subjects need be treated by thrombus endarterectomy, percutaneous transluminal plaque circumcision or laser treatment device indicate by intraoperative angiography;
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Chen zhong, professor
Email
chenzhong8658@vip.sina.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chen zhong, professor
Organizational Affiliation
Beijing Anzhen Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
The First Affiliated Hospital of Fujian Medical University
City
Fuzhou
State/Province
Fujian
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Guo pingfan, professor
Email
13960721962@163.com
First Name & Middle Initial & Last Name & Degree
Guo pingfan, professor
Facility Name
Hainan General Hospital
City
Haikou
State/Province
Hainan
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xiao Zhanxiang, professor
Email
xiaozhanxianghn@sina.com
First Name & Middle Initial & Last Name & Degree
Xiao Zhanxiang, professor
Facility Name
Hebei General Hospital
City
Shijiazhuang
State/Province
Hebei
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shi xiaoming, a. professor
Email
shixiaoming1999@126.com
First Name & Middle Initial & Last Name & Degree
Shi xiaoming, a.professor
Facility Name
The First Hospital of Hebei Medical University
City
Shijiazhuang
State/Province
Hebei
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhang Lei, professor
Email
drleizhang@163.com
First Name & Middle Initial & Last Name & Degree
Zhang Lei, professor
Facility Name
Xiangya Hospital Central South University
City
Changsha
State/Province
Hunan
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Huang jianhua, professor
Email
huangjianhua@medmail.com.cn
First Name & Middle Initial & Last Name & Degree
Huang jianhua, professor
Facility Name
Jiangsu Province Hospital
City
Nanjing
State/Province
Jiangsu
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhang Xiwei, professor
Email
xiwei1092@163.com
First Name & Middle Initial & Last Name & Degree
Zhang Xiwei, professor
Facility Name
The Second Affiliated Hospital of Nanchang University
City
Nanchang
State/Province
Jiangxi
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhou weimin, professor
Email
drzwm@sina.com
First Name & Middle Initial & Last Name & Degree
Zhou weimin, professor
Facility Name
The First Affiliated Hospital of Xi'an Jiaotong University
City
Xi'an
State/Province
Shanxi
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tian Hongyan, professor
Email
tianhhyyxg@163.com
First Name & Middle Initial & Last Name & Degree
Tian Hongyan, professor
Facility Name
West China Hospital, Sichuan University
City
Chengdu
State/Province
Sichuan
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhao
Email
xgwkzjc@163.com
First Name & Middle Initial & Last Name & Degree
Jichun
First Name & Middle Initial & Last Name & Degree
Zhao Jichun, professor
Facility Name
Beijing Anzhen Hospital Capital Medical University
City
Beijing
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
zhong Chen
Email
chenzhong8658@vip.sina.com
Facility Name
Beijing Chao-Yang Hospital
City
Beijing
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhang wangde, professor
Email
drwangde@vip.sina.com
First Name & Middle Initial & Last Name & Degree
Zhang wangde, professor
Facility Name
Beijing Frendship Hospital, Capital Medical University
City
Beijing
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chen xueming, professor
Email
chenxueming04@sohu.com
First Name & Middle Initial & Last Name & Degree
Chen xueming, professor
Facility Name
Beijing Hospital
City
Beijing
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Li Yongjun, professor
Email
yongjun.li@foxmail.com
First Name & Middle Initial & Last Name & Degree
Li Yongjun, professor
Facility Name
Beijing Shijitan Hospital, Capital Medical University
City
Beijing
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Luo Xiaoyun, A. professor
Email
paperWord@vip.163.com
First Name & Middle Initial & Last Name & Degree
Luo Xiaoyun, A. professor
Facility Name
Chinese PLA General Hospital
City
Beijing
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Guo wei, professor
Email
pla301dml@vip.sina.com
First Name & Middle Initial & Last Name & Degree
Guo wei, professor
Facility Name
Fuwai Hospital, Chinese Accadamy of Medical Sciences
City
Beijing
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shu Chang, professor
Email
changshu@yahoo.com
First Name & Middle Initial & Last Name & Degree
Shu Chang, professor
Facility Name
Renji Hospital Shanghai Jiaotong University School of Medicine
City
Shanghai
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhang Lan, professor
Email
lucky200207@aliyun.com
First Name & Middle Initial & Last Name & Degree
Zhang Lan, professor
Facility Name
Shanghai Ninth people's Hospital, Shanghai Jiaotong University School of Medicine
City
Shanghai
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jiang mi'er, professor
Email
jiangme2013@163.com
First Name & Middle Initial & Last Name & Degree
Jiang mi'er, professor
Facility Name
Tianjing Medical University General Hospital
City
Tianjin
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dai xiangchen, professor
Email
13302165917@163.com
First Name & Middle Initial & Last Name & Degree
Dai xiangchen, professor

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

A Study of Below The Knee Arteries' Stenosis or Occlusion Treated With LEGFLOW OTW

We'll reach out to this number within 24 hrs